The Trustees of the University of Pennsylvania were awarded a $299,099 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research into Metabolic Target Identification in Age-Associated B Cells from May 1, 2023 through April 30, 2025. As part of the Military Medical Research and Development program's goals of transforming military and public health care through innovative medical research, this...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $4,239,889.00 to support the development of an oral enzymatic therapy adjunctive to the dietary management of celiac disease. The award is granted to Enteralia Bioscience LLC, located in Holden, MA, and has a performance period from Jul 1, 2024 to Jun 30, 2027. The overall objective of this research initiative is to develop an innovative oral...
The University of Pennsylvania's Clinical Practices is the recipient of a $861,250 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 30, 2024, supports the advancement of mechanistic understanding of autoimmunity in aplastic anemia through HLA allele specificity research. The project aims to provide critical insights that could lead to improved treatments for this medical condition, with a...
This $1,199,997.00 Project Grant award from the Defense Health Agency, under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), is funding research to prevent trauma-related infections during prolonged care. The grant was awarded on Sep 30, 2023 to The Trustees Of The University Of Pennsylvania - doing business as Clinical Practices Of The University Of Pennsylvania, a private university and non-profit research institution. The research aims to develop...
The University of Pennsylvania received a $2,060,500 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on "VALIDATION OF NOVEL DRIVERS OF JUVENILE POLYPOSIS SYNDROME". The award period is from September 1, 2023 to August 31, 2027. Through this Project Grant, the University of Pennsylvania will perform biomedical research to investigate innovative solutions for healthcare challenges facing U.S. service...
The Department of the Army Medical Command has awarded a $384,063 Project Grant to The Pennsylvania State University (Penn State) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The two-year grant, with a performance period from February 1, 2025 to January 31, 2027, will support research on the direct genetic modification of Plasmodium sporozoites using mRNA/lipid nanoparticles. This innovative biomedical research aims to transform healthcare for military...
This $1,096,866 project grant was awarded on August 15, 2023 by the Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420). The grant, titled "TARGETING BRANCHED CHAIN AMINO ACIDS IN KIDNEY CANCER," will be carried out by The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, over a 3-year period ending on August 14, 2026. The funding supports biomedical...
This federal Project Grant award in the amount of $1,605,638.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant was awarded to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, a private research university and academic medical center. The grant funding supports research aimed at developing new methods for immune targeting of dormant tumor...
This $1,178,136 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research by The Trustees of the University of Pennsylvania (Clinical Practices of the University of Pennsylvania) to exploit the absence of TP53 mutations in epithelial ovarian cancer using next-generation p53-stabilizing agents. The research aims to develop innovative approaches to disease prevention, diagnosis, treatment, and...
The Trustees of the University of Pennsylvania received a $812,344 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research on A Novel Inflammatory Mediator for Rheumatoid Arthritis from July 15, 2021 through July 14, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and...